🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: ESSDAI

Found 12 matching trials

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

PHASE3

Primary Objective: To evaluate the effect of dazodalibep on systemic manif...

Status

Active Not Recruiting

Location

Arizona Arthritis & Rheumatology Associates - Avondale

Start Date

2024-01-24

Trial ID

NCT06104124

Treatments Being Tested

Dazodalibep Placebo

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

PHASE3

The purpose of this study is to demonstrate the efficacy and safety of iana...

Status

Recruiting

Location

Sun Valley Arthritis Center Ltd

Start Date

2026-07-16

Trial ID

NCT07621809

Treatments Being Tested

VAY736 Placebo

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

PHASE2

This study did evaluate the safety,tolerability and preliminary therapeutic...

Status

Completed

Location

Novartis Investigative Site

Start Date

2014-10-22

Trial ID

NCT02291029

Treatments Being Tested

CFZ533 active - Cohort 1 CFZ533 placebo- Cohort 1 CFZ533 active - Cohort 2 CFZ533 placebo - Cohort 2 CFZ533 active -Cohort 3 CFZ533 active - Cohort 3

Fatigue in Primary Sjögren's Syndrome

N/A

Fatigue is a common clinical finding in Primary Sjögren's syndrome (PSS). I...

Status

Completed

Location

Koray Ayar

Start Date

2021-01-04

Trial ID

NCT04802577

Treatments Being Tested

FACT-F questionnaire Beck Depression Inventory Beck Anxiety Inventory Insomnia severity index.ESSPRI ESSDAI Pain Detect Questionnaire

Efficacy and Safety of Baricitinib in Sjogren's Syndrome

PHASE2

The investigators had observed that baricitinib was effective and safe in a...

Status

Completed

Location

Peking Union Medical College Hospital

Start Date

2022-07-14

Trial ID

NCT05016297

Treatments Being Tested

Baricitinib Hydroxychloroquine

An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)

PHASE2

Sjogren's syndrome (SS) is a chronic, multisystem autoimmune disease charac...

Status

Withdrawn

Location

Universitair Medisch Centrum Utrecht /ID# 214029

Start Date

2020-03-06

Trial ID

NCT05217472

Treatments Being Tested

Ravaglimab Ravagalimab Placebo Placebo

Sjögren and Gynecologic Considerations

N/A

Sjögren's syndrome is an autoimmune disorder characterized by glandular and...

Status

Completed

Location

Ankara City Hospital

Start Date

2021-03-01

Trial ID

NCT05670535

Treatments Being Tested

Visual analogue scale (VAS) for dyspareunia Visual analogue scale (VAS) for vaginal dryness The European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)The European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI)

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

PHASE2

To evaluate efficacy, safety, and tolerability of DDY391 up to 52 weeks in ...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2026-08-27

Trial ID

NCT07737743

Treatments Being Tested

DDY391 Placebo

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

PHASE2

This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and ...

Status

Completed

Location

North GA Rheumatology Group PC

Start Date

2019-10-01

Trial ID

NCT03905525

Treatments Being Tested

CFZ533 Placebo

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

PHASE3

Primary Objective: To evaluate the effect of dazodalibep on patient-report...

Status

Active Not Recruiting

Location

Arizona Arthritis & Rheumatology Associates - Avondale

Start Date

2024-04-08

Trial ID

NCT06245408

Treatments Being Tested

Dazodalibep Placebo

Previous Next